PKD1 and autosomal dominant polycystic kidney disease: Song et al. [116] evaluated the combined effects of salsalate and tolvaptan in a PKD1 mutant mouse model; the combination therapy attenuated kidney injury, cell proliferation, inflammation, and fibrosis more effectively than either agent alone, findings which underscore the potential of salsalate, especially in combination therapies, to modulate disease progression in ADPKD.